129 related articles for article (PubMed ID: 1524956)
1. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer.
Fujimoto T; Omote K; Mai M; Natsuume-Sakai S
Biotherapy; 1992; 5(2):153-63. PubMed ID: 1524956
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
[TBL] [Abstract][Full Text] [Related]
3. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
6. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.
Nakamura H; Ishiguro K; Mori T
Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676
[TBL] [Abstract][Full Text] [Related]
7. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
Ebihara T; Fukao K; Koyama S
Cancer; 1990 Sep; 66(5):923-9. PubMed ID: 2167147
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
[TBL] [Abstract][Full Text] [Related]
10. Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells.
Shimizu Y; Kuroki T; Shiomi S; Kobayashi K; Monna T
J Gastroenterol Hepatol; 1991; 6(5):485-90. PubMed ID: 1657242
[TBL] [Abstract][Full Text] [Related]
11. Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.
Koyama S; Ebihara T; Fukao K; Osuga T
Jpn J Cancer Res; 1989 Feb; 80(2):150-7. PubMed ID: 2498249
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer].
An W
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients.
Karimine N; Nanbara S; Arinaga S; Asoh T; Ueo H; Akiyoshi T
J Surg Oncol; 1994 Mar; 55(3):179-85. PubMed ID: 8176929
[TBL] [Abstract][Full Text] [Related]
14. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
[TBL] [Abstract][Full Text] [Related]
15. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
Kan N; Okino T; Nakanishi M; Satou K; Mise K; Ohgaki K; Hori T; Kodama H; Tobe T
Hum Cell; 1988 Sep; 1(3):289-96. PubMed ID: 2979206
[TBL] [Abstract][Full Text] [Related]
16. Induction of endogenous lymphokine-activated killer activity by combined administration of lentinan and interleukin 2.
Suzuki M; Higuchi S; Taki Y; Taki S; Miwa K; Hamuro J
Int J Immunopharmacol; 1990; 12(6):613-23. PubMed ID: 2272726
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
Kruse CA; Mitchell DH; Lillehei KO; Johnson SD; McCleary EL; Moore GE; Waldrop S; Mierau GW
Cancer; 1989 Oct; 64(8):1629-37. PubMed ID: 2790675
[TBL] [Abstract][Full Text] [Related]
18. [Studies on adoptive immunotherapy using recombinant interleukin 2].
Sugiyama Y; Takao H; Saji S; Sakata K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer.
Yano T; Sugio K; Yamazaki K; Kase S; Yamaguchi M; Ondo K; Yoshino I; Sugimachi K
Lung Cancer; 1999 Dec; 26(3):143-8. PubMed ID: 10598924
[TBL] [Abstract][Full Text] [Related]
20. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2.
Kim KH; Lee YS; Jung IS; Park SY; Chung HY; Lee IR; Yun YS
Planta Med; 1998 Mar; 64(2):110-5. PubMed ID: 9525101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
